Acadian Asset Management LLC Has $4.59 Million Stock Position in Progyny, Inc. $PGNY

Key Points

• Acadian Asset Management LLC significantly increased its stake in Progyny, Inc. by 243.6%, acquiring an additional 145,802 shares and now owning approximately 0.24% of the company valued at $4.59 million.
• Progyny's shares received several analyst upgrades, with target prices raised to as much as $28.00, reflecting a positive outlook on the company's stock performance.
• The company reported a miss on earnings with an EPS of $0.19 for the recent quarter, compared to the estimated $0.42, despite achieving revenue of $332.87 million, exceeding expectations.

Acadian Asset Management LLC increased its position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 243.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 205,650 shares of the company's stock after acquiring an additional 145,802 shares during the period. Acadian Asset Management LLC owned about 0.24% of Progyny worth $4,589,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Millennium Management LLC boosted its position in shares of Progyny by 7.5% during the 1st quarter. Millennium Management LLC now owns 1,302,890 shares of the company's stock worth $29,107,000 after acquiring an additional 90,367 shares in the last quarter. Voloridge Investment Management LLC boosted its position in Progyny by 85.5% in the fourth quarter. Voloridge Investment Management LLC now owns 1,197,993 shares of the company's stock valued at $20,665,000 after buying an additional 552,066 shares in the last quarter. Bank of America Corp DE boosted its position in Progyny by 3.7% in the fourth quarter. Bank of America Corp DE now owns 952,777 shares of the company's stock valued at $16,435,000 after buying an additional 33,668 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Progyny by 8.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 689,443 shares of the company's stock valued at $15,402,000 after buying an additional 51,810 shares in the last quarter. Finally, Wellington Management Group LLP boosted its position in Progyny by 67.7% in the first quarter. Wellington Management Group LLP now owns 660,982 shares of the company's stock valued at $14,766,000 after buying an additional 266,853 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company's stock.

Insider Buying and Selling at Progyny

In other Progyny news, EVP Allison Swartz sold 2,398 shares of Progyny stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $22.96, for a total value of $55,058.08. Following the completion of the sale, the executive vice president directly owned 79,697 shares of the company's stock, valued at approximately $1,829,843.12. The trade was a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Kevin K. Gordon sold 2,500 shares of Progyny stock in a transaction on Monday, August 11th. The shares were sold at an average price of $22.04, for a total transaction of $55,100.00. Following the completion of the sale, the director directly owned 12,501 shares of the company's stock, valued at approximately $275,522.04. This trade represents a 16.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,895 shares of company stock valued at $179,311. Insiders own 9.40% of the company's stock.

Progyny Price Performance

NASDAQ PGNY traded down $0.90 during mid-day trading on Friday, reaching $21.62. 2,774,631 shares of the stock were exchanged, compared to its average volume of 928,052. Progyny, Inc. has a one year low of $13.39 and a one year high of $26.76. The stock has a 50 day simple moving average of $22.92 and a 200-day simple moving average of $22.20. The stock has a market cap of $1.86 billion, a P/E ratio of 36.64, a P/E/G ratio of 1.84 and a beta of 1.33.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing analysts' consensus estimates of $0.42 by ($0.23). Progyny had a return on equity of 10.69% and a net margin of 4.28%.The firm had revenue of $332.87 million for the quarter, compared to the consensus estimate of $315.70 million. During the same period in the prior year, the business earned $0.17 EPS. Progyny's quarterly revenue was up 9.5% on a year-over-year basis. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. Sell-side analysts anticipate that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Leerink Partnrs upgraded shares of Progyny from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 8th. Leerink Partners raised shares of Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price target for the company in a research note on Tuesday, July 8th. Raymond James Financial set a $28.00 price target on shares of Progyny in a research note on Friday, August 8th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $28.00 price target (up previously from $26.00) on shares of Progyny in a research note on Friday, August 8th. Finally, JPMorgan Chase & Co. raised their price target on shares of Progyny from $23.00 to $25.00 and gave the company a "neutral" rating in a research note on Tuesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $25.44.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.